Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Essential Hypertension and a Concomitant Disease Left Ventricular Hypertrophy

NCT00607633 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00607633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00607633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Essential Hypertension and a Concomitant Disease Left Ventricular Hypertrophy
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
January 31, 2007
Completion date
October 31, 2007
Enrollment
686 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension, left ventricular hypertrophy